| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99215 |
Prolong outpt/office vis |
42,807 |
39,519 |
$7.93M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,145 |
12,121 |
$2.29M |
| S9083 |
Global fee urgent care centers |
9,522 |
8,823 |
$1.31M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
42,643 |
40,142 |
$810K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
47,014 |
34,417 |
$681K |
| 99205 |
Prolong outpt/office vis |
3,513 |
3,298 |
$548K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,769 |
2,568 |
$518K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
23,618 |
22,503 |
$251K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,548 |
1,431 |
$228K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,796 |
2,484 |
$223K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,936 |
1,833 |
$157K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,497 |
2,234 |
$132K |
| 71046 |
Radiologic examination, chest; 2 views |
2,494 |
2,383 |
$113K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
422 |
402 |
$75K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,299 |
2,159 |
$74K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
455 |
428 |
$58K |
| 73610 |
|
287 |
274 |
$18K |
| 94664 |
|
1,464 |
1,355 |
$17K |
| 81001 |
|
2,496 |
2,340 |
$14K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
573 |
539 |
$13K |
| 74019 |
|
246 |
242 |
$12K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
583 |
528 |
$11K |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
50 |
50 |
$8K |
| 73630 |
|
179 |
172 |
$7K |
| 84703 |
|
239 |
220 |
$5K |
| 87807 |
|
632 |
590 |
$4K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,559 |
2,427 |
$2K |
| 87581 |
|
696 |
661 |
$2K |
| 73110 |
|
42 |
42 |
$2K |
| 87077 |
|
476 |
453 |
$2K |
| 12011 |
|
13 |
13 |
$2K |
| 73564 |
|
14 |
12 |
$2K |
| 85027 |
|
98 |
94 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
434 |
420 |
$1K |
| 73140 |
|
87 |
86 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,023 |
1,888 |
$801.56 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
115 |
114 |
$599.33 |
| 29125 |
|
12 |
12 |
$432.58 |
| 51701 |
|
14 |
13 |
$347.33 |
| 29130 |
|
12 |
12 |
$276.28 |
| 29515 |
|
12 |
12 |
$225.00 |
| 87045 |
|
15 |
14 |
$193.27 |
| 87486 |
|
574 |
545 |
$91.09 |
| 69209 |
|
12 |
12 |
$44.62 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
114 |
109 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
79 |
73 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
44 |
28 |
$0.00 |
| 85007 |
|
94 |
90 |
$0.00 |
| 87186 |
|
389 |
373 |
$0.00 |